Project Pipeline

  • Discovery
  • Lead
    Identification
  • Lead
    Optimization
  • Pre-clinical Development
  • Clinical Development
  • Transbuccal Insulin
  • Glucagon-like-peptide (GLP-1)
  • Insulin/GLP-1 Combination
  • Diabetes Immunotherapy
  • Oncology
  • Tumor Vaccines

Pipeline

Diabetes Pipeline

Tranbuccal Insulin

CLINICAL DEVELOPMENT
With its partner Monosol Rx, Midatech’s most advanced programme takes advantage of the fact that binding a peptide hormone to a gold nanoparticle (GNP) enables the needle-free delivery of insulin across the mucosa of the cheek. A Phase II clinical study is planned to start in 2014.

Glucagon-like-peptide (GLP-1)

PRE-CLINICAL DEVELOPMENT
Midatech has successfully bound glucagon-like-peptide [GLP-1] to GNPs for the treatment of Type 2 diabetes mellitus. The company has commenced pre-clinical research in this area and has generated promising early stage results.

Insulin/GLP-1 Combination

PRE-CLINICAL DEVELOPMENT
A combination treatment in which insulin and GLP-1 are delivered on the same GNPs has also been developed and showed positive results in pre-clinical studies.

Diabetes Immunotherapy

DISCOVERY
As part of a €6 million EU Framework 7 consortium grant, Midatech is developing a therapeutic vaccine using its GNP technology to inhibit the autoimmune destruction of pancreatic β-cells. The project was initiated in September 2012.

Oncology Pipeline

Ovarian Cancer

LEAD OPTIMIZATION
This project focuses on the development of GNPs which include folic acid (FA) and a platinum cytotoxic compound to specifically target ovarian cancer cells and is supported by a Spanish CDTI-grant.

Brain Cancer

LEAD OPTIMIZATION
Having demonstrated the specific migration of GNPs to the brain through the blood-brain-barrier, Midatech is optimizing nanoparticles combined with chemotherapeutic agents that will allow a new generation of therapeutic options for diseases such as glioblastoma.

Liver Cancer

LEAD OPTIMIZATION
Midatech has developed GNPs to specifically target the liver. Studies are currently underway to evaluate structure activity relationships with a number of payloads including doxorubicin, docetaxel and camptothecin.

Tumour Vaccines

LEAD OPTIMIZATION
Midatech is actively pursuing a therapeutic vaccine for non-small cell lung cancer based on its GNP technology. Studies were started in 2010 linking tumour-specific antigens to GNPs and investigating their potential to induce specific cytotoxic T-cell responses. 

Copyright 2013 Midatech